Novo Seeds returned for a series B round that will support the progress of NorthSea Therapeutics' lead liver disease candidate through clinical trials.

The eye disease drug developer has closed a round led by existing backer Boehringer Ingelheim Venture Fund to take its total funding above $42m.

After five years focusing on life sciences investments for GV, Vineeta Agarwala has taken a general partner role at Andreessen Horowitz.

Paris Descartes University's gene therapy developer has raised $42.1m altogether following a series B featuring existing investors including Inserm Transfert Initiative.

Samsung, SIG and OP Financial contributed to $144m in funding, raised across two rounds, for digital health technology producer Zhiyun Health.

Corporate-backed healthcare app developer Finc Technologies has raised $46.1m in fresh funding that will fund marketing and business development, bringing its overall financing to more than $138m.

Darren Carroll has emerged from a short sabbatical following 22 years in corporate venturing for Eli Lilly by joining Polaris Partners.

LG CNS and Kakao Ventures chipped into a $25.7m round for the medical imaging-analysis platform developer, boosting its overall funding to $46m.

Weizmann Institute of Science has become the latest academic research institution to join forces with Deerfield Management for a drug discovery program.

ETH Zurich's portfolio attracted a record $649m in funding last year, and the university also spawned more businesses year-on-year.